<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340831</url>
  </required_header>
  <id_info>
    <org_study_id>PTL-901895</org_study_id>
    <nct_id>NCT03340831</nct_id>
  </id_info>
  <brief_title>Continuous Monitoring and Control of Hypoglycemia</brief_title>
  <acronym>COACH</acronym>
  <official_title>Post Approval Study for Non-Adjunctive Use of Dexcom G5 CGM System for Diabetes Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DexCom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate safety of non-adjunctive CGM use in CGM naive participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study comprises recruitment and consenting of pediatric and adult participants. At entry,
      the following information will be collected: demographics, labs, clinical and diabetes
      history information (history of mild/severe hypoglycemia or DKA events in the past 6 months
      and SMBG testing frequency). There are 3 clinic visits: Study Entry, Month 6 and Month 12 .
      Monthly phone contacts will be made to assess for any mild/severe hypoglycemic or DKA events
      and any details surrounding an event. Clinic visits at Months 6 and 12 will capture frequency
      of SMBG testing, A1C level and PRO information. CGM data will be obtained during the study to
      assess for CGM adherence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">May 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hypoglycemic events</measure>
    <time_frame>6 months</time_frame>
    <description>Change in average number of hypoglycemic events per patient between CGM use compared to BGM use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in A1C</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change in A1C lab between CGM use period compared to BGM use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in incidence of hypoglycemic events</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change of participants with at least one event between CGM use period compared to BGM use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GMSS PRO scores</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change in mean scores for the Glucose monitoring satisfaction survey (GMSS) [Emotional and Trust subscales] between CGM use period compared to BGM use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetes Distress Scale (DDS) PRO scores</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change in mean scores for the DDS between CGM use period compared to BGM use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hypoglycemia Fear PRO scores</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change in mean scores for the Hypoglycemia Fear Survey between CGM use period compared to BGM use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hypoglycemia Confidence PRO scores</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change in mean scores for the Hypoglycemia Confidence Scale between CGM use period compared to BGM use period.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1388</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>CGM/BGM Group</arm_group_label>
    <description>single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring (CGM)</intervention_name>
    <description>Use of CGM to compare incidence of diabetes events compared to use of a blood glucose meter (BGM)</description>
    <arm_group_label>CGM/BGM Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults and pediatrics (2 or older), naïve to CGM, with Type 1 or insulin-requiring Type 2
        diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naïve to real-time CGM

          -  Type 1 or insulin-requiring Type 2 diabetes

          -  ≥ 2 years old

        Exclusion Criteria:

          -  Use of RT-CGM, within the past 12 months

          -  Pregnancy

          -  Concomitant disease or condition that may compromise patient safety including and not
             limited to severe mental illness, a diagnosed or suspected eating disorder or any
             uncontrolled long term medical condition that would interfere with study related tasks
             or visits, or ongoing treatment for a significant malignancy.

          -  Known (or suspected) significant allergy to medical grade adhesives

          -  Dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eileen Casal, RN, MSN</last_name>
    <phone>8588759774</phone>
    <email>ecasal@Dexcom.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Arant</last_name>
    <phone>8582036209</phone>
    <email>tom.arant@dexcom.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sansum</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Frase</last_name>
    </contact>
    <investigator>
      <last_name>Kristin Castorino, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Boyd, PA-C</last_name>
    </contact>
    <investigator>
      <last_name>Bruce Bode, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes &amp; Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Sulik</last_name>
      <phone>208-522-6005</phone>
      <email>mark@idahomed.com</email>
    </contact>
    <investigator>
      <last_name>David Liljenquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Diabetes &amp; Endocrinology Research Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Herrold, RN</last_name>
      <phone>515-643-5122</phone>
      <email>therrold@iderc.com</email>
    </contact>
    <investigator>
      <last_name>Anuj Bhargava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrine Associates, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Rahman</last_name>
      <phone>402-561-2662</phone>
      <email>jennifer.rahman@deomaha.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Konigsberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mountain Diabetes and Endocrine Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlin Ramsey</last_name>
      <phone>828-684-9588</phone>
      <phone_ext>7</phone_ext>
      <email>kramsey@mdecresearch.com</email>
    </contact>
    <investigator>
      <last_name>Wendy Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amarillo Medical Specialists, LLP</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Cota, RN, CDE</last_name>
      <phone>806-358-8331</phone>
      <email>becky.cota@amarillomed.com</email>
    </contact>
    <investigator>
      <last_name>William Biggs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satanya Brooks</last_name>
      <phone>214-265-2137</phone>
      <email>tbrooks@researchdallas.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Aronoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Research Associates</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Wahlen</last_name>
      <phone>801-409-2040</phone>
      <email>hilary@advresearch.org</email>
    </contact>
    <investigator>
      <last_name>Jack Wahlen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

